Reduced heart failure-related healthcare costs with Furoscix versus in-hospital intravenous diuresis in heart failure patients: the FREEDOM-HF study
- PMID: 37609913
- DOI: 10.2217/fca-2023-0071
Reduced heart failure-related healthcare costs with Furoscix versus in-hospital intravenous diuresis in heart failure patients: the FREEDOM-HF study
Abstract
Aim: Compare heart failure (HF) costs of Furoscix use at home compared with inpatient intravenous (IV) diuresis. Patients & methods: Prospective, case control study of chronic HF patients presenting to emergency department (ED) with worsening congestion discharged to receive Furoscix 80 mg/10 ml 5-h subcutaneous infusion for ≤7 days. 30-day HF-related costs in Furoscix group derived from commercial claims database compared with matched historical patients hospitalized for <72 h. Results: Of 24 Furoscix patients, 1 (4.2%) was hospitalized in 30-day period. 66 control patients identified and were well-matched for age, sex, ejection fraction (EF), renal function and other comorbidities. Furoscix patients had reduced mean per patient HF-related healthcare cost of $16,995 (p < 0.001). Conclusion: Furoscix use was associated with significant reductions in 30-day HF-related healthcare costs versus matched hospitalized controls.
Keywords: Furosemide; congestion; diuretics; emergency department; heart failure; subcutaneous.
Plain language summary
What is this article about? In heart failure (HF), the heart cannot pump as well as it should. This causes blood to back up in the vessels that return blood to the heart. Fluid leaks from these vessels and collects in vital organs such as the lungs. This fluid build-up is called congestion. Congestion causes symptoms such as shortness of breath, tiredness and leg swelling. Furoscix is a prescription medicine, a diuretic, that treats congestion. Diuretics help get rid of extra fluid by increasing urination. Congestion is usually managed with oral diuretics, but sometimes congestion cannot be controlled by oral diuretics and patients may have to spend several days at a clinic or hospital to receive diuretics given through a vein (intravenous or iv.). Furoscix is a new formulation of furosemide, a common diuretic, and is delivered into the skin (subcutaneous) by a self-administered pump instead of through an iv. Our investigation aimed to answer two questions Can Furoscix be given to patients at home instead of in the hospital with iv. diuretics? Is there a cost savings to using Furoscix? Instead of being admitted to the hospital for iv. diuretics, HF patients with worsening congestion who came to the emergency department were sent home to receive Furoscix 80 mg/10 ml 5-h subcutaneous infusion for ≤7 days. 30-day costs related to HF in these patients were compared with costs from similar group of patients previously hospitalized for iv. diuretics. What were the results & what do they mean? In patients who needed to be admitted to the hospital for iv. diuretics, Furoscix given at home instead reduced congestion and resulted in significant cost savings. Patients with heart failure, who are not getting relief with oral diuretics, can be treated with Furoscix at home without having to be admitted to the hospital for iv. diuretics. Use of Furoscix instead of iv. furosemide can save money to the healthcare system.
Similar articles
-
Diuretic efficiency of a single dose of subcutaneous versus oral furosemide after heart failure hospitalization across diuretic resistance strata: A pilot randomized controlled trial.Eur J Heart Fail. 2025 Feb;27(2):347-352. doi: 10.1002/ejhf.3537. Epub 2024 Dec 2. Eur J Heart Fail. 2025. PMID: 39620306 Free PMC article. Clinical Trial.
-
Avoiding Treatment in Hospital With Subcutaneous Furosemide for Worsening Heart Failure: A Pilot Study (AT HOME-HF).JACC Heart Fail. 2024 Nov;12(11):1830-1841. doi: 10.1016/j.jchf.2024.07.015. Epub 2024 Sep 11. JACC Heart Fail. 2024. PMID: 39269392 Clinical Trial.
-
Management of heart failure in cardiac amyloidosis using an ambulatory diuresis clinic.Am Heart J. 2021 Mar;233:122-131. doi: 10.1016/j.ahj.2020.12.009. Epub 2020 Dec 22. Am Heart J. 2021. PMID: 33352187
-
A novel opportunity to improve heart failure care: focusing on subcutaneous furosemide.Heart Fail Rev. 2023 Nov;28(6):1315-1323. doi: 10.1007/s10741-023-10331-4. Epub 2023 Jul 13. Heart Fail Rev. 2023. PMID: 37439967 Review.
-
Outpatient treatment of worsening heart failure with intravenous and subcutaneous diuretics: a systematic review of the literature.ESC Heart Fail. 2020 Jun;7(3):892-902. doi: 10.1002/ehf2.12677. Epub 2020 Mar 11. ESC Heart Fail. 2020. PMID: 32159279 Free PMC article.
Cited by
-
Subcutaneous furosemide in heart failure: a systematic review.Eur Heart J Cardiovasc Pharmacother. 2025 Feb 8;11(1):94-104. doi: 10.1093/ehjcvp/pvae083. Eur Heart J Cardiovasc Pharmacother. 2025. PMID: 39520561 Free PMC article.
-
Diuretic efficiency of a single dose of subcutaneous versus oral furosemide after heart failure hospitalization across diuretic resistance strata: A pilot randomized controlled trial.Eur J Heart Fail. 2025 Feb;27(2):347-352. doi: 10.1002/ejhf.3537. Epub 2024 Dec 2. Eur J Heart Fail. 2025. PMID: 39620306 Free PMC article. Clinical Trial.
-
Home intravenous diuretic administration for heart failure management: A scoping review.PLoS One. 2025 Jan 17;20(1):e0316851. doi: 10.1371/journal.pone.0316851. eCollection 2025. PLoS One. 2025. PMID: 39823449 Free PMC article.
-
Human Factors Validation of a Wearable, On-Body Infusor for Subcutaneous Administration of Furosemide.Med Devices (Auckl). 2024 Jun 24;17:229-235. doi: 10.2147/MDER.S462573. eCollection 2024. Med Devices (Auckl). 2024. PMID: 38948076 Free PMC article.
-
Outpatient worsening heart failure: innovative decongestion strategies and health equity implications.Heart Fail Rev. 2025 Sep;30(5):831-841. doi: 10.1007/s10741-025-10509-y. Epub 2025 Apr 5. Heart Fail Rev. 2025. PMID: 40188318 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous